ERS guideline recommendation on airflow for breathlessness: the pitfalls of applying GRADE evidence ratings to complex non-pharmacological interventions
- PMID: 39915045
- DOI: 10.1183/13993003.02244-2024
ERS guideline recommendation on airflow for breathlessness: the pitfalls of applying GRADE evidence ratings to complex non-pharmacological interventions
Conflict of interest statement
Conflict of interest: T. Luckett has received competitive funding for breathlessness-related projects from Australia's National Health and Medical Research Council (NHMRC), the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) and the University of Technology Sydney (UTS) Faculty of Health. M. Roberts has received personal honoraria for after-hours lectures and presentations on the management of breathlessness from the Lung Foundation Australia and Boehringer Ingelheim. M. Crooks has received grants from the National Institute for Health and Care Research, Asthma+Lung UK, AstraZeneca, Boehringer Ingelheim, Chiesi, Phillips and Pfizer, honoraria, fees and/or non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Orion, Novartis, Pfizer, Synairgen and Sanofi. The remaining authors have no potential conflicts of interest to declare.
Comment on
-
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness.Eur Respir J. 2024 Jun 28;63(6):2400335. doi: 10.1183/13993003.00335-2024. Print 2024 Jun. Eur Respir J. 2024. PMID: 38719772
Publication types
LinkOut - more resources
Full Text Sources